117 related articles for article (PubMed ID: 8555441)
1. Chronometaanalysis: circasemiseptan (3.5-day) pattern in mitotic activity of murine sarcoma after treatment with cyclophosphamide.
Focan C; Cornélissen G; Halberg F
In Vivo; 1995; 9(4):401-6. PubMed ID: 8555441
[TBL] [Abstract][Full Text] [Related]
2. Circasemiseptan (about-half-weekly) and/or circaseptan (about-weekly) pattern in human mitotic activity?
Blank M; Cornélissen G; Halberg F
In Vivo; 1995; 9(4):391-4. PubMed ID: 8555439
[TBL] [Abstract][Full Text] [Related]
3. The week in phylogeny and ontogeny: opportunities for oncology.
Halberg F
In Vivo; 1995; 9(4):269-78. PubMed ID: 8555425
[TBL] [Abstract][Full Text] [Related]
4. Use of synchronization induced by cyclophosphamide in a methylcholanthrene sarcoma with circadian proliferation to rational sequential chemotherapy.
Focan C; Barbason H; Betz EH
Biomedicine; 1975 Jun; 23(6):230-5. PubMed ID: 1240011
[TBL] [Abstract][Full Text] [Related]
5. X-irradiation chronosensitivity and circadian rhythmic proliferation in healthy and sarcoma-carrying rats' bone marrow.
Blank MA; Gushchin VA; Halberg F; Portela A; Cornélissen G
In Vivo; 1995; 9(4):395-400. PubMed ID: 8555440
[TBL] [Abstract][Full Text] [Related]
6. Marker rhythms for cancer chronotherapy. From laboratory animals to human beings.
Focan C
In Vivo; 1995; 9(4):283-98. PubMed ID: 8555427
[TBL] [Abstract][Full Text] [Related]
7. [Chronobiology and cancer].
Lévi F
Pathol Biol (Paris); 1987 Jun; 35(6):960-8. PubMed ID: 3306577
[TBL] [Abstract][Full Text] [Related]
8. Chronobiology, growth hormone and healthy and malignant growth.
Halberg F; Lakatua D; Lodeiro C; Garcia L; Hermida R; Ayala DE; Tarquini B; Haus E; Cornélissen G
J Endocrinol Invest; 1989; 12(8 Suppl 3):41-7. PubMed ID: 2681347
[TBL] [Abstract][Full Text] [Related]
9. [Diurnal variations in the response of cells to factors altering mitotic activity].
Alov IA
Usp Sovrem Biol; 1978; 86(2):216-26. PubMed ID: 364862
[No Abstract] [Full Text] [Related]
10. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature.
Segers J; Di Fazio V; Ansiaux R; Martinive P; Feron O; Wallemacq P; Gallez B
Cancer Lett; 2006 Nov; 244(1):129-35. PubMed ID: 16426744
[TBL] [Abstract][Full Text] [Related]
11. Seasonal modulation of the 8-and 24-hour rhythms of ondansetron tolerance in mice.
Khedhaier A; Ben-Attia M; Gadacha W; Sani M; Reinberg A; Boughattas NA
Chronobiol Int; 2007; 24(6):1199-212. PubMed ID: 18075807
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.
Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):186-92. PubMed ID: 12203100
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.
Eto M; Harano M; Tatsugami K; Harada M; Kamiryo Y; Kiyoshima K; Hamaguchi M; Tsuneyoshi M; Yoshikai Y; Naito S
Clin Cancer Res; 2007 Feb; 13(3):1029-35. PubMed ID: 17289899
[TBL] [Abstract][Full Text] [Related]
14. Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics.
Wood PA; Hrushesky WJ; Klevecz R
Exp Hematol; 1998 Jun; 26(6):523-33. PubMed ID: 9620286
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials: the larger the better?
Halberg F; Bingham C; Cornélissen G
Chronobiologia; 1993; 20(3-4):193-211. PubMed ID: 8131669
[TBL] [Abstract][Full Text] [Related]
16. [Effect of monochromatic red lighting potentiating antitumor action of cyclophosphamide injected with autoblood].
Sheĭko EA; Shikhliarova AI
Vopr Onkol; 2011; 57(4):493-6. PubMed ID: 22191240
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
18. Optimization of the chronotherapeutic index in the experimental animal laboratory.
Halberg E; Cornélissen G; Halberg F
In Vivo; 1992; 6(4):371-85. PubMed ID: 1520840
[TBL] [Abstract][Full Text] [Related]
19. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.
Tsung K; Meko JB; Tsung YL; Peplinski GR; Norton JA
J Immunol; 1998 Feb; 160(3):1369-77. PubMed ID: 9570556
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
